Breast Cancer Research · 2011 · 336 citations · 50 references
MedicineCancer BiologyOncologyBreast OncologyMolecular OncologyNeoplasiaCancer BiomarkersCancer GenomicsCancer TranscriptomicsExpression Signature DiscoveryMalignant NeoplasmsMolecular Classification Of TumorsBreast Cancer GenomicsBreast Cancer Molecular SubtypesCancer Subtype DiscoveryHistological Grade PrognosisPrognostic Expression SignaturesPrognostic Tumor MarkersTumor ProfilingTumor-specific Biomarkers
INTRODUCTION: Current prognostic gene expression profiles for breast cancer mainly reflect proliferation status and are most useful in ER-positive cancers. Triple negative breast cancers (TNBC) are clinically heterogeneous and prognostic markers and biology-based therapies are needed to better treat this disease. METHODS: We assembled Affymetrix gene expression data for 579 TNBC and performed unsupervised analysis to define metagenes that distinguish molecular subsets within TNBC. We used n = 394 cases for discovery and n = 185 cases for validation. Sixteen metagenes emerged that identified basal-like, apocrine and claudin-low molecular subtypes, or reflected various non-neoplastic cell populations, including immune cells, blood, adipocytes, stroma, angiogenesis and inflammation within the cancer. The expressions of these metagenes were correlated with survival and multivariate analysis was performed, including routine clinical and pathological variables. RESULTS: Seventy-three percent of TNBC displayed basal-like molecular subtype that correlated with high histological grade and younger age. Survival of basal-like TNBC was not different from non basal-like TNBC. High expression of immune cell metagenes was associated with good and high expression of inflammation and angiogenesis-related metagenes were associated with poor prognosis. A ratio of high B-cell and low IL-8 metagenes identified 32% of TNBC with good prognosis (hazard ratio (HR) 0.37, 95% CI 0.22 to 0.61; P < 0.001) and was the only significant predictor in multivariate analysis including routine clinicopathological variables. CONCLUSIONS: We describe a ratio of high B-cell presence and low IL-8 activity as a powerful new prognostic marker for TNBC. Inhibition of the IL-8 pathway also represents an attractive novel therapeutic target for this disease.
50
Molecular portraits of human breast tumours
Charles M. Perou, Thérese Sørlie, Michael B. Eisen et al. · Nature · 2000 · 16.3K citations
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
Marc J. van de Vijver, Yudong D. He, Laura van ‘t Veer et al. · New England Journal of Medicine · 2002 · 6.5K citations · Full text
Medicine, Bioinformatics, Oncology +17
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
Soonmyung Paik, Steven Shak, Gong Tang et al. · New England Journal of Medicine · 2004 · 6.4K citations · Full text
Medicine, Oncology, Breast Oncology +12
Ki67 expression in breast cancer
Mohamed A. Elkablawy, Abdulkader M. Albasri, Rabab Mohammed et al. · Saudi Medical Journal · 2016 · 4.4K citations · Full text